Bausch & Lomb Corp 8K

Bausch + Lomb reconstituted its board at the request of majority owner Bausch Health, reported strong Q2 2026 results, and reaffirmed its increased full‑year 2026 guidance.

On August 6, 2026, Bausch + Lomb Corporation announced that, at the request of its 87% majority owner Bausch Health Companies Inc., its board of directors appointed four new directors—Thomas J. Appio, Robert Chersi, Laurence Paul, MD, and Barbara Trebbi—effective August 5, 2026, replacing four resigning directors whose departures were not due to any disagreement with the company; in the same release, the company reported strong second‑quarter 2026 financial performance with $1.394 billion in revenue (9% year‑over‑year growth), significantly improved cash flow from operations, highlighted progress on its diversified R&D and product pipeline, and reaffirmed its previously raised full‑year 2026 revenue and Adjusted EBITDA guidance.

Filing Facts

CIK

1860742

Ticker

-

Form

8K

Source Type

sec

Accession

0000950103-26-011979

Alert Tier

5